Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance
Iridex Corporation (Nasdaq: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases, has successfully regained compliance with Nasdaq's continued listing requirements. The company had received a non-compliance notice on May 14, 2025, due to falling below the minimum stockholders' equity requirement of $2.5 million based on their Q1 2025 10-Q filing.
On August 27, 2025, Nasdaq formally confirmed that Iridex had regained compliance with Rule 5550(b)(1) following the company's Q2 2025 10-Q filing on August 12, 2025, which demonstrated sufficient stockholders' equity. The compliance matter has been resolved and closed.
Iridex Corporation (Nasdaq: IRIX), fornitore di sistemi medici laser per il glaucoma e le malattie retiniche, ha nuovamente ottemperato ai requisiti di quotazione continuativa del Nasdaq. La società aveva ricevuto un avviso di non conformità il 14 maggio 2025, per essere scesa sotto il requisito minimo di patrimonio netto di $2,5 milioni in base al modulo 10-Q relativo al primo trimestre 2025.
Il 27 agosto 2025 Nasdaq ha confermato formalmente che Iridex ha ripristinato la conformità alla Regola 5550(b)(1), dopo che il modulo 10-Q relativo al secondo trimestre 2025, depositato il 12 agosto 2025, ha evidenziato un patrimonio netto sufficiente. La questione di conformità è stata risolta e chiusa.
Iridex Corporation (Nasdaq: IRIX), proveedor de sistemas médicos láser para el glaucoma y enfermedades de la retina, ha recuperado con éxito el cumplimiento de los requisitos de cotización continuada del Nasdaq. La compañía había recibido un aviso de incumplimiento el 14 de mayo de 2025 por situarse por debajo del requisito mínimo de patrimonio neto de $2,5 millones, según su presentación 10-Q del primer trimestre de 2025.
El 27 de agosto de 2025 Nasdaq confirmó formalmente que Iridex había recuperado el cumplimiento de la Norma 5550(b)(1) tras la presentación del 10-Q del segundo trimestre de 2025, el 12 de agosto de 2025, que mostró un patrimonio neto suficiente. El asunto de cumplimiento ha sido resuelto y cerrado.
Iridex Corporation (Nasdaq: IRIX)는 녹내장 및 망막 질환용 레이저 의료 시스템 제공업체로, 나스닥의 상장 유지 요건을 다시 충족하게 되었습니다. 회사는 2025년 1분기 10-Q 제출서에 근거해 주주지분이 최소 요구치인 $250만 아래로 떨어져 2025년 5월 14일 비적합 통지를 받았습니다.
나스닥은 2025년 8월 27일, 2025년 8월 12일 제출된 2025년 2분기 10-Q에서 충분한 주주지분이 확인됨에 따라 Iridex가 규칙 5550(b)(1)의 적합성을 회복했음을 공식적으로 확인했습니다. 해당 적합성 문제는 해결되어 종결되었습니다.
Iridex Corporation (Nasdaq: IRIX), fournisseur de systèmes médicaux laser pour le glaucome et les affections rétiniennes, a rétabli sa conformité aux exigences de maintien en cotation du Nasdaq. La société avait reçu un avis de non-conformité le 14 mai 2025, après être tombée en dessous du seuil minimum de capitaux propres de 2,5 millions de $ selon son 10-Q du premier trimestre 2025.
Le 27 août 2025, le Nasdaq a confirmé formellement qu'Iridex avait retrouvé la conformité à la règle 5550(b)(1) suite au dépôt du 10-Q du deuxième trimestre 2025 le 12 août 2025, qui a démontré des capitaux propres suffisants. La question de conformité a été résolue et classée sans suite.
Iridex Corporation (Nasdaq: IRIX), ein Anbieter laserbasierter medizinischer Systeme für Glaukom und Netzhauterkrankungen, hat die Anforderungen für die fortgeführte Notierung an der Nasdaq wieder erfüllt. Das Unternehmen hatte am 14. Mai 2025 eine Nichtkonformitätsmitteilung erhalten, weil das Eigenkapital laut dem 10-Q für Q1 2025 unter der Mindestanforderung von $2,5 Millionen lag.
Am 27. August 2025 bestätigte die Nasdaq formell, dass Iridex die Konformität mit Regel 5550(b)(1) wiedererlangt hat, nachdem das 10-Q für Q2 2025 am 12. August 2025 vorgelegt wurde und ausreichendes Eigenkapital nachgewiesen hat. Die Compliance-Angelegenheit ist somit gelöst und abgeschlossen.
- Company has regained Nasdaq listing compliance
- Successfully met minimum stockholders' equity requirement of $2.5 million
- Previously fell below Nasdaq's minimum stockholders' equity requirement
MOUNTAIN VIEW, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced that it has received formal notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that Iridex has evidenced compliance with the continued listing requirements.
As previously reported, on May 14, 2025, Iridex received a notification of non-compliance from Nasdaq’s Listing Qualifications Department notifying the Company that, based upon its quarterly report on Form 10-Q for the quarterly period ended March 29, 2025 that was filed with the Securities and Exchange Commission (the “SEC”) on May 13, 2025, the Company was not in compliance with the continued listing standards set forth in Nasdaq Listing Rule 5550(b).
On August 27, 2025, the Company received formal notification from Nasdaq confirming that the Company had regained compliance with the continued listing standards of Nasdaq Listing Rule 5550(b) by satisfying the minimum stockholders’ equity requirement of
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2025 Iridex Corporation. All rights reserved.
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
What was the reason for Iridex (IRIX) Nasdaq non-compliance notice in May 2025?
When did Iridex (IRIX) regain Nasdaq listing compliance?
What is the minimum stockholders' equity requirement for Nasdaq Capital Market listing?
What does Iridex Corporation (IRIX) do?
